EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

HIV-associated kidney diseases: progress, gaps, and future directions

Molly C Fisher iD, Christina M Wyatt, Michelle M Estrella

Clinical Microbiology Reviews · 12.03.2026 · 39 (1)

DOI: 10.1128/cmr.00207-25 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical Microbiology Reviews, erschienen am 12.03.2026. Verfasst von Molly C Fisher und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, Montefiore Medical Center/ Albert Einstein College of Medicine, Bronx, New York, USA. Hauptthemen laut MEDLINE: HIV Infections, Renal Insufficiency, Chronic, AIDS-Associated Nephropathy. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 181 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCATS NIH HHS, NIDDK NIH HHS, National Center for Advancing Translational Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

With improved uptake and earlier initiation of effective antiretroviral therapy (ART), the landscape of chronic kidney disease (CKD) among people with HIV (PWH) has substantially evolved. HIV-driven kidney diseases, particularly HIV-associated nephropathy (HIVAN), have largely disappeared in regions with widespread ART availability. However, CKD remains an important comorbidity among PWH because of the increased prevalence of age-related conditions such as diabetes and hypertension, which are established CKD risk factors. Whether contemporary ART regimens that have lower metabolic and kidney toxicity will lower this burden over time remains unclear. In low-resourced areas, these age-related conditions are compounded by persistent disparities in access to ART, co-infections, and limited resources for CKD screening and management. Early detection and management of CKD are crucial to slowing CKD progression and averting its related cardiovascular complications. The past several years have ushered in several new therapies that both lower the risk for CKD progression and adverse cardiovascular events, underscoring the importance of kidney function and albuminuria testing in those at high risk of CKD or CKD progression. For PWH who unfortunately progress to end-stage kidney disease, kidney transplantation now offers improved survival but requires careful management of immunosuppressive regimens and infectious complications. This review will discuss the current understanding of the epidemiology, pathogenesis, diagnosis, and management of kidney diseases in PWH.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV InfectionsRenal Insufficiency, ChronicAIDS-Associated NephropathyHumansRisk Factors

Stichwörter der Autor:innen

HIV-associated nephropathyagingantiretroviral therapykidney disease

Autor:innen und Institutionen

  • Division of Nephrology, Montefiore Medical Center/ Albert Einstein College of Medicine, Bronx, New York, USA.
  • Division of Nephrology, Duke University, Durham, North Carolina, USA.
  • Division of Nephrology and Kidney Health Research Collaborative, Department of Medicine, University of California San Francisco, San Francisco, California, USA.

ORCID-Profile: Molly C Fisher

Förderung

  • NCATS NIH HHS
  • NIDDK NIH HHS
  • National Center for Advancing Translational Sciences
  • National Institute of Diabetes and Digestive and Kidney Diseases

Zitieren

APA

Fisher, M. C., Wyatt, C. M., & Estrella, M. M. (2026). HIV-associated kidney diseases: progress, gaps, and future directions. Clinical Microbiology Reviews, 39(1). https://doi.org/10.1128/cmr.00207-25

Vancouver

Fisher MC, Wyatt CM, Estrella MM. HIV-associated kidney diseases: progress, gaps, and future directions. Clinical Microbiology Reviews. 2026;39(1). doi:10.1128/cmr.00207-25

BibTeX
@article{Fisher2026,
  author = {Fisher, Molly C and Wyatt, Christina M and Estrella, Michelle M},
  title = {HIV-associated kidney diseases: progress, gaps, and future directions},
  journal = {Clinical Microbiology Reviews},
  year = {2026},
  volume = {39},
  number = {1},
  doi = {10.1128/cmr.00207-25}
}
Kostenlos starten →